Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (201 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1116

201 publications

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 201 publications

Nature, 2020, 17

PubMed: 32555459 ( click the link to review the publication )

Cell, 2020, 16;181(2):424-441.e21.

PubMed: 32234521 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Cell, 2018, 9;34(1):56-68.e9

PubMed: 29990501 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Nat Commun, 2020, 2;11(1):2760

PubMed: 32488085 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-0943-5

PubMed: 32591645 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6)

PubMed: 32236513 ( click the link to review the publication )

J Cell Biol, 2020, 2;219(3)

PubMed: 32211891 ( click the link to review the publication )
Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Cancers (Basel), 2020, 6;12(4)

PubMed: 32268485 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Cells, 2020, 26;9(4)

PubMed: 32225025 ( click the link to review the publication )

Cancer Discov, 2020, 13;CD-19-1390

PubMed: 32404308 ( click the link to review the publication )

Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:280

PubMed: 32624705 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):89

PubMed: 32795346 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0236298

PubMed: 32701996 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01403-y

PubMed: 32712628 ( click the link to review the publication )

J Pathol, 2020, e5493

PubMed: 32558936 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

Clin Transl Med, 2020, 10(1):182-198

PubMed: 32508030 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa653

PubMed: 32761127 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )
Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e11031

PubMed: 31512803 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

Sci Signal, 2019, 12(601):eaay0482

PubMed: 31575731 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )
Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )
Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )
Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

J Mol Cell Biol, 2017, 1;9(2):154-165

PubMed: 27927748 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )
Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005829

PubMed: 27541004 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2016, 310(7):C520-41

PubMed: 26718628 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )
Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Anticancer Res, 2015, 35(12):6623-32

PubMed: 26637878 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Blood, 2014, 3;124(1):13-23

PubMed: 24764564 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

J Immunol, 2014, 193(4):1988-97

PubMed: 25015816 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

PLoS Genet, 2013, 9(5):e1003546

PubMed: 23737759 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2722-34

PubMed: 24107447 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )
Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Clin Cancer Res, 2011, 1;17(13):4513-22

PubMed: 21593195 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	M136O2tqdmG\|ZTDBd5NigQ>?		NEDZd48zPCCq		M2S3TmlvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh\|ryP	NICxVZMzPDZ2MUGwNy=>
COLO205	NIXsfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEO2c284OiCq		M2rG[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO	MV6yOFY1OTFyMx?=
U937	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV23NkBp		NYHLcWxISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>?	NVXKepl6OjR4NEGxNFM>
MOLM13	NUPlUXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX3Ed2c{PzJiaB?=		M{D6NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR\|IFnUSEBufXSjboSgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0>	M{Pjd\|I1PjRzMUCz
MOLM13	M2nJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mny0O\|IhcA>?		MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO	M2fNUVI1PjRzMUCz
MDA-MB-435	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWeyOEBp		MlvKTWM2OD1yLkG2JO69VQ>?	MlzmNVU5ODF6M{G=
K562	NF6yfHlEgXSxdH;4bYMhSXO\|YYm=		MmD4PVYhcA>?	MknDSG1UVw>?	M3jsZ2lEPTB;MjFOwG0>	NX;1NI4zOjR2MUe1OlY>
DU145	MVvDfZRwfG:6aXOgRZN{[Xl?		NXntToNOQTZiaB?=	MljkSG1UVw>?	NGTiN2JKSzVyPUeuOUDPxE1?	M1vXZlI1PDF5NU[2
MDA-MB-231	M3jE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLWXFYyKM7:TR?=	MkDDNlQhcA>?	NEfBOI5FVVOR	NFzUOHBE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	NV\DS4FmOjR2MUe1OlY>
MCF7	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHyzV5MyKM7:TR?=	NYPXOHBXOjRiaB?=	MnvZSG1UVw>?	MV3D[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS\|EheGijc3W=	NWn5N4duOjR2MUe1OlY>
MCF7	Ml\mT4lv[XOnIFHzd4F6	M1zGelUh\|ryP	NIr1ZpkzPCCq	MVzEUXNQ	NF;kS49KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG\|dH;tZUBxcG:\|cHjvdplt[XSrb36gZZQhW2W{N{iw	M{H3d\|I1PDF5NU[2
MDA-MB-231	NF;hSlBMcW6jc3WgRZN{[Xl?	M{\tNVUh\|ryP	NEH3O5YzPCCq	M4P2O2ROW09?	NGC3OpBKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG\|dH;tZUBxcG:\|cHjvdplt[XSrb36gZZQhW2W{N{iw	NXzzXIhEOjR2MUe1OlY>
MDA-MB-231	M13ob2Z2dmO2aX;uJGF{e2G7	M4PIPFEuOTBizszN	NIr6doIzPCCq	M37VW2ROW09?	MnHS[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen	NIi5dVMzPDRzN{W2Oi=>
MCF7	NXHyWJh4TnWwY4Tpc44hSXO\|YYm=	NFTiZmIyNTFyIN88US=>	MXWyOEBp	M32yOGROW09?	MYfkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?	M1H3SVI1PDF5NU[2
MDA-MB-231	MWrGeY5kfGmxbjDBd5NigQ>?	MUSwMlUuOSEQvF2=	NXXvS3JJPDhiaB?=	MoXoSG1UVw>?	NVvrV\|lRcGG\|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V?	MXGyOFQyPzV4Nh?=
MCF7	MoWzSpVv[3Srb36gRZN{[Xl?	NYTtZXB5OC53LUGg{txO	NXu1U4FxPDhiaB?=	NHTJblVFVVOR	NETrb25p[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>?	Mk\mNlQ1OTd3Nk[=
697	Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrqcZVKSzVyPUG0PE4{QCCwTR?=	M2\oZnNCVkeHUh?=
P12-ICHIKAWA	NFu3enlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPCUlRKSzVyPUm2MlA1KG6P	M2rVNXNCVkeHUh?=
NB69	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTF4MT64JI5O	M3jJPXNCVkeHUh?=
EoL-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{faZ2lEPTB;MUi3MlI3KG6P	NVjZNI1bW0GQR1XS
BHT-101	M4fIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfSTFFoUUN3ME2xPVgvOjVibl2=	MmDEV2FPT0WU
SK-NEP-1	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD6UJlOUUN3ME2yNlAvODJibl2=	NInWb5ZUSU6JRWK=
MHH-NB-11	NHTLSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJ{MD6xPUBvVQ>?	M2KzN3NCVkeHUh?=
AsPC-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXwTJdKSzVyPUK1Nk42OyCwTR?=	NW\4e5dvW0GQR1XS
ES1	M2Xib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoO5TWM2OD1{NU[uNlUhdk1?	NGL0U\|RUSU6JRWK=
LAMA-84	NEjhVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTJ3OD6xPUBvVQ>?	MVjTRW5ITVJ?
MOLT-16	NWD3XoZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETubWJKSzVyPUK1PE41QSCwTR?=	NUCyXHhCW0GQR1XS
ES7	NUDQdIRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTJ5Mz6wPUBvVQ>?	MXPTRW5ITVJ?
KY821	MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDL[ohKSzVyPUOxOE4yKG6P	M{OzXXNCVkeHUh?=
RT-112	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTN{MT6wOUBvVQ>?	MlTUV2FPT0WU
HL-60	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXTZZVKSzVyPUO0NE43PiCwTR?=	MVfTRW5ITVJ?
MOLT-4	MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzHeG5lUUN3ME2zOFUvOTNibl2=	Mk\pV2FPT0WU
KARPAS-45	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTNV\|lSUUN3ME2zO\|YvOTZibl2=	MUTTRW5ITVJ?
SK-N-AS	NV\kfI5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7kcoNKSzVyPUO4O{45OyCwTR?=	MWjTRW5ITVJ?
CTB-1	NVzofJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIG4Z4pKSzVyPUSwOU4xOiCwTR?=	NYXVTolOW0GQR1XS
NKM-1	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkL1TWM2OD12MUGuPFkhdk1?	MVjTRW5ITVJ?
HTC-C3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTR\|Mj65OUBvVQ>?	M{TMcXNCVkeHUh?=
BE-13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnXXmlKSzVyPUS0OE4zPyCwTR?=	M2fOOnNCVkeHUh?=
KOSC-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTR4Nj65JI5O	M3PpRXNCVkeHUh?=
NB14	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;tWpJKSzVyPUS4N{42QCCwTR?=	MmDQV2FPT0WU
CAL-27	NETCdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTR7ND61PUBvVQ>?	MYnTRW5ITVJ?
H9	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlOzTWM2OD12OUWuOFMhdk1?	NG[5N5VUSU6JRWK=
RS4-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT2TWM2OD13MESuO\|Mhdk1?	MVfTRW5ITVJ?
PA-1	M33tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXWTWM2OD13MEmuPFYhdk1?	M1LpUXNCVkeHUh?=
MV-4-11	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPBWllKSzVyPUWxN{45PSCwTR?=	NFHCbVNUSU6JRWK=
OS-RC-2	NVKyUXZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXXXlZoUUN3ME21NlEvPjJibl2=	M3LFPXNCVkeHUh?=
RPMI-8226	NHOwbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3X4eWlEPTB;NUK2Mlg3KG6P	M1uzPHNCVkeHUh?=
HGC-27	NUfmW2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELLXpNKSzVyPUW2OE46QSCwTR?=	M4PMR3NCVkeHUh?=
CHP-212	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPDfm9KSzVyPUW5N{42QSCwTR?=	NI\FXXZUSU6JRWK=
NB10	NEfYcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7YOlFCUUN3ME21PVkvOThibl2=	M1u1cXNCVkeHUh?=
HH	Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTV7OT60N{BvVQ>?	MlfaV2FPT0WU
EW-16	MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonaTWM2OD14MEOuOVIhdk1?	NXe4UpRbW0GQR1XS
ES8	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTlUpVWUUN3ME22NFUvOjFibl2=	M1XY[3NCVkeHUh?=
HAL-01	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTZyNT62O{BvVQ>?	M4LZOXNCVkeHUh?=
A204	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\l[oNKSzVyPU[zN{46OSCwTR?=	MkfjV2FPT0WU
MHH-PREB-1	M2XEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4L1NGlEPTB;NkO2Mlk6KG6P	NHfvVldUSU6JRWK=
EM-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfOTWM2OD14NUCuOlQhdk1?	MX3TRW5ITVJ?
BV-173	NUTM[\|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3kR2xKUUN3ME22OVIvPDhibl2=	NXW5dnNUW0GQR1XS
ONS-76	NETFSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFj1PHVKSzVyPU[3O{45OiCwTR?=	NHHXOYpUSU6JRWK=
KM-H2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTZ7NT61OEBvVQ>?	Mo\tV2FPT0WU
D-263MG	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fmV2lEPTB;N{G3MlEzKG6P	MoX5V2FPT0WU
ES3	M17lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofaTWM2OD15MkiuPVMhdk1?	MWDTRW5ITVJ?
VA-ES-BJ	M1LaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVznb3RbUUN3ME23N\|IvOjdibl2=	NWLDbZJOW0GQR1XS
NBsusSR	NUHhWW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYe0eXBtUUN3ME23OFIvQTlibl2=	M17KXHNCVkeHUh?=
NCI-H520	NVTtWY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3W4XGlEPTB;N{S2MlUzKG6P	M3j3SHNCVkeHUh?=
ES5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvGOXBKSzVyPUe1Nk45KG6P	NF:2ZnNUSU6JRWK=
T-24	NGfLSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn2TWM2OD15N{iuO\|Ehdk1?	M4nWPXNCVkeHUh?=
SW962	M4HyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPrbIRKSzVyPUiwPE43OyCwTR?=	M1uwTnNCVkeHUh?=
EW-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nXUWlEPTB;OEC4Mlc3KG6P	NULWO2tOW0GQR1XS
RXF393	M4TnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfZO4poUUN3ME24NVIvPzlibl2=	MYHTRW5ITVJ?
U251	NYX1[pd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzyTWM2OD16MUOuPFghdk1?	MorJV2FPT0WU
CAMA-1	NX3aWY8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITZS3RKSzVyPUizN{46PCCwTR?=	MYfTRW5ITVJ?
JVM-3	NHfGRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTh3MT63PEBvVQ>?	MnPXV2FPT0WU
COLO-800	NGLQOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTh7Nz63PEBvVQ>?	Mk[1V2FPT0WU
OVCAR-5	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTlyMD6xJI5O	MmPmV2FPT0WU
LB1047-RCC	NVjTeWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXyVHR5UUN3ME25NlcvPTZibl2=	Mm[wV2FPT0WU
SW954	NVzoXG1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWD4NZZHUUN3ME25NlkvPDFibl2=	NVv2eFE6W0GQR1XS
J-RT3-T3-5	M2rlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPsTWM2OD17M{[uNFYhdk1?	NF7LZZdUSU6JRWK=
Mewo	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;nfmlEPTB;OUO2MlYhdk1?	Mm\vV2FPT0WU
NCI-H1770	NEDBWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M162WmlEPTB;OUSwMlU2KG6P	MUXTRW5ITVJ?
HO-1-N-1	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLG[lFKSzVyPUm2Nk45OSCwTR?=	NVLWbVNmW0GQR1XS
HSC-3	NXjR[VdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTl4Nj60PEBvVQ>?	MVXTRW5ITVJ?
TYK-nu	M1O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXITXljUUN3ME25PVgvOjVibl2=	NXnrb4J5W0GQR1XS
KYSE-150	NIjFR\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4f6RWlEPTB;MT6wNFA4PiEQvF2=	NYroeXRJW0GQR1XS
SN12C	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLFToR7UUN3ME2xMlAxQDd3IN88US=>	MXnTRW5ITVJ?
MOLT-13	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHkTWM2OD1zLkCxOFIyKM7:TR?=	Mnq5V2FPT0WU
TE-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HOfGlEPTB;MT6wOFgyOiEQvF2=	MX3TRW5ITVJ?
DB	M163c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTQeYRKSzVyPUGuNFczPzNizszN	NXXONXRUW0GQR1XS
CAL-39	NHGyUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXVcZdKSzVyPUGuNFc2OjJizszN	MWLTRW5ITVJ?
A3-KAW	NEHIfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWe0d2xpUUN3ME2xMlA5PDB6IN88US=>	Mn3TV2FPT0WU
CHP-134	MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTxTWM2OD1zLkGxPFA4KM7:TR?=	MVTTRW5ITVJ?
TGW	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzmTWM2OD1zLkGyN\|k2KM7:TR?=	Mmm2V2FPT0WU
QIMR-WIL	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjRS3ZKSzVyPUGuNVMyOzRizszN	Mln1V2FPT0WU
NCI-SNU-1	NXK1OVlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfkbY5SUUN3ME2xMlE3OzV2IN88US=>	MmCzV2FPT0WU
CGTH-W-1	NFfEbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1KxZWlEPTB;MT6xO\|E5PiEQvF2=	NWLpUI1xW0GQR1XS
MHH-ES-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXOTWM2OD1zLkG3PVg3KM7:TR?=	NWS1ZY0xW0GQR1XS
LB2241-RCC	NIHXdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGm3R\|lKSzVyPUGuNVg3OiEQvF2=	NGLzRmdUSU6JRWK=
ML-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWS2VnhvUUN3ME2xMlIxPzN2IN88US=>	MXvTRW5ITVJ?
COR-L23	NX\XR3V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\tbHBKSzVyPUGuNlI6OzNizszN	MmDPV2FPT0WU
BFTC-905	NWPLW2xET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmT5TWM2OD1zLkK0NlY4KM7:TR?=	NH\XemVUSU6JRWK=
Hs-578-T	M{m1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{OyOGlEPTB;MT6yOVgyPyEQvF2=	NVzUW3BoW0GQR1XS
KG-1	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33DRWlEPTB;MT6yOlY5PiEQvF2=	NXK4PG5KW0GQR1XS
HEL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwMkmzN\|gh\|ryP	MU\TRW5ITVJ?
A549	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTFwMkmzPVkh\|ryP	NFPWcYNUSU6JRWK=
COLO-741	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFwM{KwPFkh\|ryP	MmryV2FPT0WU
PC-3	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFwM{WyNlEh\|ryP	M13oVXNCVkeHUh?=
HOS	MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFwM{WyPVYh\|ryP	NWjYO2ZZW0GQR1XS
HT-1080	MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{OyUWlEPTB;MT6zO\|UyQSEQvF2=	MY\TRW5ITVJ?
TE-8	M4W5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjLR2dKSzVyPUGuOFE4PzRizszN	MYnTRW5ITVJ?
BHY	M1r0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33TTmlEPTB;MT60OlkzOyEQvF2=	M{Pn[3NCVkeHUh?=
BB65-RCC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jTV2lEPTB;MT61NFUzQCEQvF2=	NFO1eFRUSU6JRWK=
HN	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFwNUSwO\|Eh\|ryP	MnfYV2FPT0WU
NCI-H441	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDieWFKSzVyPUGuOVQ6ODdizszN	MYPTRW5ITVJ?
RPMI-8866	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFwNUi1NFch\|ryP	NWj4V4duW0GQR1XS
CAL-62	MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXoNpRLUUN3ME2xMlYxQDZ{IN88US=>	NUe1XGNSW0GQR1XS
MG-63	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoK5TWM2OD1zLk[xPFE{KM7:TR?=	NWexVWxEW0GQR1XS
SK-LU-1	NVzjfmduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rKS2lEPTB;MT62NlE2OiEQvF2=	MYjTRW5ITVJ?
BCPAP	M2jheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;l[ppMUUN3ME2xMlY3PDV5IN88US=>	M4npTnNCVkeHUh?=
22RV1	NInZR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnS0TWM2OD1zLk[3PFQ{KM7:TR?=	M2nxdHNCVkeHUh?=
T47D	NXfvOIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTFwNkiwOlEh\|ryP	MmPuV2FPT0WU
MSTO-211H	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEm0TY1KSzVyPUGuOlk3ODNizszN	M2DzOHNCVkeHUh?=
DEL	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3NdGFKSzVyPUGuO\|AzPzNizszN	MkLqV2FPT0WU
H4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTFwN{OyNVIh\|ryP	MWnTRW5ITVJ?
CAL-51	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PoZmlEPTB;MT63OFg2PSEQvF2=	Ml61V2FPT0WU
ABC-1	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGS1[mVKSzVyPUGuO\|g2QDJizszN	M1:4bXNCVkeHUh?=
MZ2-MEL	M{Thb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XTUmlEPTB;MT63PVU1OiEQvF2=	NX;zdFlWW0GQR1XS
YKG-1	NVnJUlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTFwOEGwOlEh\|ryP	MljUV2FPT0WU
KM12	M4X2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rpUGlEPTB;MT64NVYxOiEQvF2=	M1G2XnNCVkeHUh?=
L-363	M1vafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTFwOEe0NVIh\|ryP	MVrTRW5ITVJ?
KU812	M2T6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\HTWM2OD1zLki5NlgzKM7:TR?=	NWDZUolMW0GQR1XS
LOXIMVI	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHKVmJKSzVyPUGuPVEzOjhizszN	NIfFO\|NUSU6JRWK=
G-401	NXu0SFRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjpbHZiUUN3ME2xMlkzPDJ6IN88US=>	MVrTRW5ITVJ?
SW780	NVzOcWtMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLlfZhpUUN3ME2xMlk3OjR4IN88US=>	MkP4V2FPT0WU
SW872	NGDCO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXGUG5KSzVyPUGuPVg{OyEQvF2=	NXS1enJuW0GQR1XS
NB7	NITDVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFwOUmzNlMh\|ryP	MmfHV2FPT0WU
T98G	MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HBVWlEPTB;Mj6wNFY3PiEQvF2=	NFnC[FlUSU6JRWK=
SW1710	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXjepJKSzVyPUKuNFY6PDVizszN	MlixV2FPT0WU
NCI-H1573	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJwMEeyPVgh\|ryP	MWfTRW5ITVJ?
KE-37	NIHYZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fDWGlEPTB;Mj6wPFk2OSEQvF2=	NGmyellUSU6JRWK=
786-0	M4rGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX1NXFKSzVyPUKuNVU1OzlizszN	Mnf1V2FPT0WU
SAS	NFL2N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJwMkCzO\|Qh\|ryP	M1\zZnNCVkeHUh?=
CAL-54	M3LqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXrZVZKSzVyPUKuNlA1OTNizszN	MYXTRW5ITVJ?
SF268	MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJwMkOxNlIh\|ryP	NULJSZF[W0GQR1XS
SW620	M4f6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rzdWlEPTB;Mj6yOlE3QSEQvF2=	NHPUfIhUSU6JRWK=
MN-60	NHLYdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW0VW1KSzVyPUKuN\|ExPiEQvF2=	M3Hj[3NCVkeHUh?=
EFO-27	NYnDN4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzMTWM2OD1{LkOyNFU5KM7:TR?=	MXrTRW5ITVJ?
NCI-H747	M3;M[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoiwTWM2OD1{LkOyNVk6KM7:TR?=	NYm0RXNnW0GQR1XS
HCC2218	NIfCVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P5RmlEPTB;Mj6zOVM4PCEQvF2=	MoXQV2FPT0WU
MIA-PaCa-2	NYDnO5VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJwM{[0N\|ch\|ryP	MlzzV2FPT0WU
SJSA-1	MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrsO\|ZKSzVyPUKuN\|c4QTZizszN	MWPTRW5ITVJ?
RKO	Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XV[2lEPTB;Mj6zPFQ6PiEQvF2=	MUDTRW5ITVJ?
NB6	NVjWd4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXxTWM2OD1{LkSwN\|c1KM7:TR?=	MYnTRW5ITVJ?
ES4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILzWllKSzVyPUKuOFU1OjJizszN	NFzBfoZUSU6JRWK=
EGI-1	NH;hfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJwNE[4PFMh\|ryP	MkfKV2FPT0WU
CTV-1	NGTrcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zHbmlEPTB;Mj61Nlc4OyEQvF2=	M4e0WHNCVkeHUh?=
NCI-H1355	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\MSW9UUUN3ME2yMlU2QTVzIN88US=>	NFnIdVNUSU6JRWK=
GT3TKB	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;xTWM2OD1{LkW5NVk6KM7:TR?=	NXPCfmJMW0GQR1XS
SK-HEP-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJwNUmyOlYh\|ryP	NHPvUG9USU6JRWK=
GAMG	NGK5SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DxSGlEPTB;Mj61PVM6PCEQvF2=	NWrsOFJ7W0GQR1XS
SK-MES-1	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PhT2lEPTB;Mj62NVgxOyEQvF2=	MWHTRW5ITVJ?
RO82-W-1	NFnHcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\oe2lEPTB;Mj62NlA2PyEQvF2=	NEPNb3ZUSU6JRWK=
ECC10	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfQcm84UUN3ME2yMlcxOjB4IN88US=>	NX;mbJFHW0GQR1XS
MCF7	NGDEd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfRTWM2OD1{LkexOFY1KM7:TR?=	NHjn[WpUSU6JRWK=
D-283MED	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPOTWM2OD1{LkeyOFMh\|ryP	Mk\YV2FPT0WU
RPMI-7951	M4G3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LHeGlEPTB;Mj63OVY6PCEQvF2=	M1rHSHNCVkeHUh?=
Ramos-2G6-4C10	NUO0T2dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HoSWlEPTB;Mj63O\|A6QSEQvF2=	M2[wU3NCVkeHUh?=
KGN	M{nzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPkS5BKSzVyPUKuPFE5QDRizszN	NH3MeXFUSU6JRWK=
NUGC-3	NWXwbnp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfBWHFKSzVyPUKuPFI2ODVizszN	M2PUTXNCVkeHUh?=
NCI-H292	NUX0S5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLZeplKSzVyPUKuPFUxPTNizszN	NUHGTYN5W0GQR1XS
Becker	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\mcGtKSzVyPUKuPVU5OzJizszN	NYC2cGhLW0GQR1XS
NCI-H1299	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTNwMEWyOlMh\|ryP	NWPTbnA4W0GQR1XS
ETK-1	M3\WO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT4WXppUUN3ME2zMlA2PDNizszN	M{m0UXNCVkeHUh?=
TK10	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rLOGlEPTB;Mz6yNFE3PSEQvF2=	MnflV2FPT0WU
VMRC-RCZ	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLqOnVPUUN3ME2zMlM3PDh6IN88US=>	MkH0V2FPT0WU
YH-13	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXOfJVwUUN3ME2zMlQ1ODd7IN88US=>	NH;NZ5VUSU6JRWK=
DU-145	NHqxbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkj1TWM2OD1\|LkS2NlY6KM7:TR?=	MormV2FPT0WU
SW1088	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jaT2lEPTB;Mz60O\|Q4KM7:TR?=	M{n6eHNCVkeHUh?=
HOP-92	NGPqSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\tTWM2OD1\|LkWwN\|QzKM7:TR?=	MWTTRW5ITVJ?
KP-N-YS	NUS4W2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13NTGlEPTB;Mz62NlE{QSEQvF2=	NXLzfo1DW0GQR1XS
NCI-H460	M4\FR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2raRWlEPTB;Mz62Olc{KM7:TR?=	NUnvSWp2W0GQR1XS
U-2-OS	M1fNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;KS\|d4UUN3ME2zMlczPTN3IN88US=>	MkXXV2FPT0WU
A101D	M4riWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTNwN{[5N\|Yh\|ryP	NVe3OXZuW0GQR1XS
MDA-MB-231	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LWbGlEPTB;Mz64NVk2OSEQvF2=	MYLTRW5ITVJ?
IST-MES1	NYLpSnE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3xVpNKSzVyPUOuPFMzKM7:TR?=	NYHRO5dzW0GQR1XS
COR-L105	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTRwMEG4JO69VQ>?	MVnTRW5ITVJ?
NCI-H1437	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTRwMEKzNFIh\|ryP	MoTOV2FPT0WU
CAL-85-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mli0TWM2OD12LkCyOFYyKM7:TR?=	MWPTRW5ITVJ?
MZ1-PC	NIC4SnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHMTWM2OD12LkG4OVU3KM7:TR?=	MlPDV2FPT0WU
VM-CUB-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrwTWM2OD12LkOxNlg1KM7:TR?=	Mn\YV2FPT0WU
CHL-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXHTWM2OD12LkOyNVY6KM7:TR?=	NIXLNXFUSU6JRWK=
MDA-MB-361	M2PaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU[3W4xMUUN3ME20MlM{OTV\|IN88US=>	NYPqbnY2W0GQR1XS
NCI-H661	NHLPTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13ETmlEPTB;ND61NFA6OiEQvF2=	M2j5[nNCVkeHUh?=
EW-11	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTRwNUKyN\|Eh\|ryP	NED3[HRUSU6JRWK=
BEN	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHqTWM2OD12LkWyPFE2KM7:TR?=	NVziUpVQW0GQR1XS
BFTC-909	M4fBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\ZeGlEPTB;ND61OlI4PSEQvF2=	MUPTRW5ITVJ?
NCI-H2087	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnLTWM2OD12LkW4NVY1KM7:TR?=	NF;Qb5hUSU6JRWK=
RVH-421	NHHFbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TEPWlEPTB;ND62OlY6KM7:TR?=	NV3PWpMxW0GQR1XS
P30-OHK	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE[xVVlKSzVyPUSuOlgxODhizszN	NWHNeoRiW0GQR1XS
NCI-H28	M2HnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf6Z5lKSzVyPUSuPFE3PjFizszN	NWnMWY5JW0GQR1XS
ES6	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDqTWM2OD12LkizNFE3KM7:TR?=	MnjzV2FPT0WU
769-P	NYj0Onh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDqTWM2OD12Lki1PVI3KM7:TR?=	M2fOV3NCVkeHUh?=
OE33	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTRwOEixOlEh\|ryP	M{DTb3NCVkeHUh?=
SW982	NXXrSWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTRwOUWwOlEh\|ryP	NUj2bWozW0GQR1XS
A388	NVHwRldUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13KZ2lEPTB;NT6wNlk5OyEQvF2=	NVy2b3dnW0GQR1XS
TI-73	NF;qb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rZ[2lEPTB;NT6wOlE6PCEQvF2=	MoHJV2FPT0WU
HCT-116	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\jTWM2OD13LkC5PFg6KM7:TR?=	NFfEOHFUSU6JRWK=
HuP-T3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTVwMUi3NFkh\|ryP	MmTxV2FPT0WU
G-402	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\5WnlpUUN3ME21MlE6PDF4IN88US=>	NWXiTFh4W0GQR1XS
NCI-H1792	NXjwRWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\HXGlEPTB;NT6yOFYzOiEQvF2=	NUXucY5ZW0GQR1XS
NCI-H209	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFO5fYNKSzVyPUWuNlU6PDJizszN	MnvOV2FPT0WU
NCI-H1650	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTVwM{C2N\|Qh\|ryP	MUPTRW5ITVJ?
LCLC-97TM1	M{jNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTVwM{G4NFgh\|ryP	MWDTRW5ITVJ?
S-117	M{LZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFqyNHhKSzVyPUWuN\|Y6PzZizszN	M37idHNCVkeHUh?=
GI-ME-N	M{LEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTVwM{m2PFEh\|ryP	MkXLV2FPT0WU
NCI-H2122	NHnPPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnP5TWM2OD13LkS5N\|k4KM7:TR?=	NF\h[GFUSU6JRWK=
NCI-H1793	NFizZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;lSWlEPTB;NT62O\|U6OyEQvF2=	NYHuT2NHW0GQR1XS
C2BBe1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jXXWlEPTB;NT63NFA5QCEQvF2=	MY\TRW5ITVJ?
TE-12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\mTWlEPTB;NT64NFU2PiEQvF2=	NIHadm9USU6JRWK=
LCLC-103H	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TDOWlEPTB;NT65NVch\|ryP	MWXTRW5ITVJ?
A673	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTVwOUG5N\|Ih\|ryP	MmjlV2FPT0WU
BB30-HNC	M{DJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHmTWM2OD13Lkm4N\|Yh\|ryP	NHGxT\|ZUSU6JRWK=
SF295	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rM[2lEPTB;Nj6wNFQzOiEQvF2=	NXTE[nZbW0GQR1XS
KU-19-19	M{TiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHjUFFkUUN3ME22MlAyPzNzIN88US=>	NEO1XXFUSU6JRWK=
CFPAC-1	M1;VeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnwR\|hKSzVyPU[uNFQ1PDNizszN	NXfvVmdTW0GQR1XS
LoVo	NXjMOVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvyTWM2OD14LkC1NFY{KM7:TR?=	M4XzfHNCVkeHUh?=
8505C	M2\5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jpdGlEPTB;Nj6wO\|U4OyEQvF2=	M{LROHNCVkeHUh?=
GMS-10	M3;leGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGj1[I9KSzVyPU[uNVUxODJizszN	MUnTRW5ITVJ?
Ca9-22	MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7aR\|BKSzVyPU[uNVY4OSEQvF2=	NFrBeXJUSU6JRWK=
DOK	NYPGWJhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETVNldKSzVyPU[uNlIxPzJizszN	M2rEfnNCVkeHUh?=
FADU	NFLmfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjTR5RKSzVyPU[uNlYxOzlizszN	NUfjfmZYW0GQR1XS
BxPC-3	NHnUeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHmbZlKSzVyPU[uNlc{OiEQvF2=	Mn;lV2FPT0WU
CAL-33	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV6xSIM3UUN3ME22MlI6OjBzIN88US=>	MlLNV2FPT0WU
SHP-77	M1nIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2X5VWlEPTB;Nj6zNVUyOiEQvF2=	MYXTRW5ITVJ?
LXF-289	M4TtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTZwM{O0OVUh\|ryP	MknpV2FPT0WU
GB-1	NYjOWVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfOTWM2OD14LkO4NkDPxE1?	NWrTVXBkW0GQR1XS
KS-1	MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGK0[W5KSzVyPU[uN\|g1PDdizszN	NH7HSFFUSU6JRWK=
D-502MG	M33tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLsTWM2OD14LkSyN\|c3KM7:TR?=	NHOycmRUSU6JRWK=
LAN-6	MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDlTWM2OD14LkWxNFI{KM7:TR?=	MX7TRW5ITVJ?
H-EMC-SS	NHXYWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfTZpdKSzVyPU[uOVYyPDdizszN	NYGwRWh7W0GQR1XS
LC-2-ad	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TnNGlEPTB;Nj62NFA4PiEQvF2=	M3uxbHNCVkeHUh?=
NCI-H1693	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnftTWM2OD14Lk[yNlE2KM7:TR?=	M3L0NnNCVkeHUh?=
SK-N-FI	M1rlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jsOGlEPTB;Nj63OVA1PCEQvF2=	M3fNS3NCVkeHUh?=
D-423MG	M1TUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkn5TWM2OD14Lke2NVE4KM7:TR?=	MkT1V2FPT0WU
KNS-42	NYnhU4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTZwN{ixPVch\|ryP	NWPudXZoW0GQR1XS
GCT	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTZwOUO4JO69VQ>?	MVPTRW5ITVJ?
DSH1	NH:wT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTdwME[zN{DPxE1?	MXPTRW5ITVJ?
D-247MG	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\JeGlEPTB;Nz6wO\|g5OSEQvF2=	MljSV2FPT0WU
NCI-SNU-5	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXTbW1KSzVyPUeuNVg{PzFizszN	MYDTRW5ITVJ?
TE-6	NYT2doU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTdwMkC2NFEh\|ryP	MoHnV2FPT0WU
NOMO-1	NFrlNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTJTWM2OD15LkKyNVI4KM7:TR?=	M1K1RnNCVkeHUh?=
NB17	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmm4TWM2OD15LkOwN\|A6KM7:TR?=	NIfZXFVUSU6JRWK=
EW-22	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTdwM{SzOFgh\|ryP	MWTTRW5ITVJ?
EW-13	NWL6cXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlK5TWM2OD15LkO1NVYzKM7:TR?=	NGTzOZBUSU6JRWK=
DOHH-2	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPRTGRKSzVyPUeuOFQxOiEQvF2=	MkmyV2FPT0WU
TGBC1TKB	MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\3SWlEPTB;Nz60PVg6QSEQvF2=	MmPvV2FPT0WU
GR-ST	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIT0eHRKSzVyPUeuOVI2QTRizszN	MUTTRW5ITVJ?
KYSE-520	NWWyeHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTdwNUW1NVUh\|ryP	NHi2UpBUSU6JRWK=
CAPAN-1	M2nzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkX4TWM2OD15LkW5OVEh\|ryP	M1rsV3NCVkeHUh?=
HCE-4	NILtT\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTdwNkKyO\|kh\|ryP	NXjTWolzW0GQR1XS
MLMA	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\EZW5IUUN3ME23MlYzQTV5IN88US=>	NVX4XndEW0GQR1XS
HT-144	M1TocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTdwNkWzOlgh\|ryP	MXnTRW5ITVJ?
KYSE-180	Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLXTWM2OD15LkexNVY6KM7:TR?=	NX3JfJlpW0GQR1XS
TE-5	NGDy[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTdwOUW5O\|Eh\|ryP	MUfTRW5ITVJ?
IGROV-1	NVzofI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnBNFNKSzVyPUeuPVg2PTFizszN	MYXTRW5ITVJ?
NCI-H1581	MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\ISW5wUUN3ME24MlAyOiEQvF2=	NV;NdpAxW0GQR1XS
SW1990	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnFTWM2OD16LkC0OlU6KM7:TR?=	NYOxb4NlW0GQR1XS
EFM-19	NUjMWmg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEn6fo9KSzVyPUiuNFg2PDVizszN	NGXMbmVUSU6JRWK=
OGR-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;rTWM2OD16LkSzNFI{KM7:TR?=	M1\0dnNCVkeHUh?=
U-118-MG	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLiTWM2OD16LkSzOFY{KM7:TR?=	M2jaR3NCVkeHUh?=
SK-OV-3	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLaflROUUN3ME24MlQ3PzZ3IN88US=>	Mne2V2FPT0WU
KNS-62	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4OyUGlEPTB;OD61NVc3OSEQvF2=	M{H3W3NCVkeHUh?=
GOTO	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jnRmlEPTB;OD61O\|Y{PSEQvF2=	MWfTRW5ITVJ?
8305C	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEX0PWRKSzVyPUiuO\|A1QDRizszN	MnP5V2FPT0WU
RPMI-2650	NHHTeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXsTWM2OD16LkexPVU2KM7:TR?=	NEHwRoRUSU6JRWK=
NEC8	NXnQdI5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPwO41zUUN3ME24Mlc1OzB5IN88US=>	MYDTRW5ITVJ?
KYSE-450	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDocXVKSzVyPUiuPFY2PDhizszN	NWjsVIg6W0GQR1XS
RMG-I	NVLUW2RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfyTWM2OD17LkG0NFU5KM7:TR?=	M3LUPXNCVkeHUh?=
CAKI-1	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rOeGlEPTB;OT6zNVk4QSEQvF2=	NI\kSI1USU6JRWK=
KYSE-510	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXK0eJkzUUN3ME25MlM2Pzd6IN88US=>	Mmi1V2FPT0WU
A4-Fuk	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL3TWM2OD17LkO2O\|AyKM7:TR?=	NUjW[mJjW0GQR1XS
AN3-CA	M3HKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLDTWM2OD17LkS1OFQ1KM7:TR?=	NHmz[oxUSU6JRWK=
SK-N-DZ	NUiyTGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHP5VXFKSzVyPUmuO\|I5PDlizszN	NEPR[ZZUSU6JRWK=
HSC-2	MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnFXVIyUUN3ME25Mlc3PjJ7IN88US=>	M3W4U3NCVkeHUh?=
EW-1	NVPJT4FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUC5d3R2UUN3ME25Mlc6OzZ7IN88US=>	MlTOV2FPT0WU
D-566MG	MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[5ZWlEPTB;OT64N\|Y3PCEQvF2=	NXjHTIJUW0GQR1XS
COLO-792	NYXQdo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTlwOUi3OFYh\|ryP	M3[0OnNCVkeHUh?=
TE-10	Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1y0SmlEPTB;MUCuNFM6PiEQvF2=	M4K4[3NCVkeHUh?=
NCI-H650	NGHXOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHtdZBKSzVyPUGwMlQzQDZizszN	MULTRW5ITVJ?
U-266	MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\3PZoyUUN3ME2xNE41PTVizszN	Mo[yV2FPT0WU
Detroit562	Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLGeVBJUUN3ME2xNU4xPTF3IN88US=>	NXzFNY5jW0GQR1XS
NH-12	NWHJSIlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jaZWlEPTB;MUGuNVQ1PiEQvF2=	NGHofIlUSU6JRWK=
CO-314	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fmUGlEPTB;MUGuNlg1OiEQvF2=	NHjmNllUSU6JRWK=
IST-MEL1	NX\xbGNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3:ydmlEPTB;MUGuOVMzOyEQvF2=	NIDmT3dUSU6JRWK=
KNS-81-FD	M3rYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrJSVdwUUN3ME2xNU42PTJ5IN88US=>	M3;CNHNCVkeHUh?=
SW1463	NF7R[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFzLkW5PFkh\|ryP	M2XWWnNCVkeHUh?=
NCI-H23	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXyTWM2OD1zMT62OVUzKM7:TR?=	NUmwUnk1W0GQR1XS
SK-MEL-2	NFLIeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ix[mlEPTB;MUGuO\|E6PyEQvF2=	MmDhV2FPT0WU
NB13	NWXkemlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHwdYxVUUN3ME2xNk4yPDl3IN88US=>	MlPtV2FPT0WU
Daoy	NIe1eWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzyXnJKSzVyPUGyMlI5PTZizszN	NYT3PWpOW0GQR1XS
NCI-H1623	NFnJOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\MfIVWUUN3ME2xNk4{QDBzIN88US=>	NE\uVJhUSU6JRWK=
NMC-G1	NH;0RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHf6ZXZKSzVyPUGyMlcyPyEQvF2=	MXjTRW5ITVJ?
DK-MG	M4rBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHVRo5KSzVyPUGyMlk1QDJizszN	NEOxSmlUSU6JRWK=
TCCSUP	NXvJWJh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPjRZFpUUN3ME2xN{4yOjh2IN88US=>	Mlz5V2FPT0WU
SCC-15	NWe0NVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTF\|LkK2OVEh\|ryP	NXHj[HpEW0GQR1XS
NOS-1	NYPWdpJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfweHJKSzVyPUGzMlI5QTNizszN	NXvJbXBUW0GQR1XS
RH-1	NI\5PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF\|LkOwN\|ch\|ryP	MnnIV2FPT0WU
SK-MEL-3	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTzdm9KUUN3ME2xN{4{PzJ6IN88US=>	NVjqNHFJW0GQR1XS
NB5	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfFbVZKSzVyPUGzMlQxPjdizszN	M4jUUnNCVkeHUh?=
SNU-387	NWnwd\|cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXj3ZY5wUUN3ME2xN{42ODd{IN88US=>	NIXn[VVUSU6JRWK=
CAL-120	NHnlT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEP3b5ZKSzVyPUGzMlY4OThizszN	M1\RNHNCVkeHUh?=
Mo-T	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTF\|LkewO{DPxE1?	NXO3dm5wW0GQR1XS
LNCaP-Clone-FGC	NFTMXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHQTWM2OD1zMz63PVkzKM7:TR?=	NH\CS2dUSU6JRWK=
CAN	M3nBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TzV2lEPTB;MUSuNFI5QCEQvF2=	M1S1UnNCVkeHUh?=
SK-MEL-30	M{PtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVT3dGF7UUN3ME2xOE4xPjNizszN	M{LQV3NCVkeHUh?=
COLO-678	M2[3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnqxTWM2OD1zND6wPFIzKM7:TR?=	NF:zS2NUSU6JRWK=
SCC-9	Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTF2LkGwNlEh\|ryP	M2fvZnNCVkeHUh?=
KINGS-1	NHP2NVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7HTWM2OD1zND6xOFAzKM7:TR?=	NEnufYNUSU6JRWK=
SL-513	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnG[ItKSzVyPUG0MlE5PyEQvF2=	M{XwNXNCVkeHUh?=
HLE	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTF2LkO4OVIh\|ryP	NUPEdmptW0GQR1XS
SW1573	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTF2LkS0N\|Uh\|ryP	M1nNZ3NCVkeHUh?=
KYSE-140	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nZR2lEPTB;MUSuOlMzPyEQvF2=	Mom0V2FPT0WU
SK-PN-DW	M1LUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnvZ\|dKSzVyPUG0MlgxODFizszN	MY\TRW5ITVJ?
A253	NEPCOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHLR5ByUUN3ME2xOU4xPjJ3IN88US=>	NHvaVGtUSU6JRWK=
CAL-12T	M3nQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF3LkS2OlIh\|ryP	NUCzfXI3W0GQR1XS
COLO-679	NVPtdGluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7XVmlKSzVyPUG1Mlc3QDNizszN	NYrK[mdpW0GQR1XS
UACC-257	NVn1bnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\nS5RFUUN3ME2xOk4yOjBzIN88US=>	NHvRXFZUSU6JRWK=
U-87-MG	NY\BdG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXrXmRLUUN3ME2xOk4{PTJ\|IN88US=>	MmD6V2FPT0WU
HCC1806	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTF4LkewO\|Eh\|ryP	NVrKPJdlW0GQR1XS
NCI-H2170	NGrlVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTlTWM2OD1zNz6yOFQ5KM7:TR?=	MVHTRW5ITVJ?
AGS	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHNU\|RrUUN3ME2xO{4{QDB6IN88US=>	MVLTRW5ITVJ?
MEL-HO	MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfLTWM2OD1zNz63OVA{KM7:TR?=	MYHTRW5ITVJ?
SW48	NX7sSIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXScYNMUUN3ME2xO{44PzF4IN88US=>	NV\4PHZrW0GQR1XS
HuP-T4	M4DnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDCZVdzUUN3ME2xPE4xOjB4IN88US=>	MnPSV2FPT0WU
NCI-H720	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWr5OohoUUN3ME2xPE4yPDB{IN88US=>	NHS2U5RUSU6JRWK=
RCC10RGB	NFfkT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELX[I1KSzVyPUG4MlE3QTdizszN	Mnu1V2FPT0WU
HD-MY-Z	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDJTWM2OD1zOD6yNlU1KM7:TR?=	NHPiN5JUSU6JRWK=
A427	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPLSVVTUUN3ME2xPE42ODl2IN88US=>	M33ydXNCVkeHUh?=
HCC2998	M13kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7YPGtTUUN3ME2xPE43ODVzIN88US=>	MkD4V2FPT0WU
EPLC-272H	M1PjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NImzNm9KSzVyPUG5MlA1OzRizszN	MX;TRW5ITVJ?
C32	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTXWmhkUUN3ME2xPU4xPDVizszN	MorWV2FPT0WU
UMC-11	M2PVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j4e2lEPTB;MUmuNlEzOyEQvF2=	MWrTRW5ITVJ?
CaR-1	NWrjSWpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULsSIZLUUN3ME2xPU43QDB2IN88US=>	NGfzXoxUSU6JRWK=
KYSE-410	MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHyTWM2OD1zOT65NVM6KM7:TR?=	MlrjV2FPT0WU
HuCCT1	NVmwU\|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJyLk[yPVQh\|ryP	NXvGN5hDW0GQR1XS
LB996-RCC	M3O2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJyLkexOlgh\|ryP	M2T1OHNCVkeHUh?=
KYSE-70	MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXacGZvUUN3ME2yNE45ODV7IN88US=>	NITTT4pUSU6JRWK=
CAL-72	NEH5NHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnLTGFTUUN3ME2yNE46OTVizszN	NHHMVYVUSU6JRWK=
Capan-2	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfDWIJ2UUN3ME2yNU4xPDF\|IN88US=>	M4n4UnNCVkeHUh?=
PANC-08-13	NW\IPJduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJzLkK1NVUh\|ryP	NWjYcIJrW0GQR1XS
SBC-1	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NECxOmxKSzVyPUKxMlMxQDFizszN	MmDQV2FPT0WU
MFM-223	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHRTWM2OD1{MT6zN\|QzKM7:TR?=	MojJV2FPT0WU
BB49-HNC	NWPGfHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILVOHlKSzVyPUKxMlU4OTZizszN	MXvTRW5ITVJ?
SH-4	NYXEUo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJzLk[2NVgh\|ryP	M1vBZ3NCVkeHUh?=
HuO9	NUf0T4FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULkNGtWUUN3ME2yNU46QDJ3IN88US=>	M4PreHNCVkeHUh?=
AM-38	M4DCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrE[JBHUUN3ME2yNk4xPDh3IN88US=>	NYe1Z5JKW0GQR1XS
A431	MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTaTWM2OD1{Mz6yNVE6KM7:TR?=	M3nLbnNCVkeHUh?=
YAPC	NIrhOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\TS4dkUUN3ME2yN{4zPjVzIN88US=>	MVvTRW5ITVJ?
LU-139	NIDIRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfXTWM2OD1{Mz60PFA6KM7:TR?=	NU\Ke3NYW0GQR1XS
HEC-1	NE[3XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;Qd\|VKSzVyPUKzMlQ6OzdizszN	M4jRXXNCVkeHUh?=
SCC-25	MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHnRlNKSzVyPUK0MlMxODZizszN	NVO5bW1{W0GQR1XS
HT-29	NYDse2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NET0coZKSzVyPUK0MlM5OjNizszN	MkLOV2FPT0WU
PC-14	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjEXpVKSzVyPUK0MlY2PzFizszN	NUD0dJJFW0GQR1XS
Calu-6	NWLLe5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13sTmlEPTB;MkWuOVA4OSEQvF2=	NI[4fJJUSU6JRWK=
SJRH30	NFTrT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7wNFM{UUN3ME2yOU43PDl4IN88US=>	MkDMV2FPT0WU
ChaGo-K-1	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJ4LkG2Nlkh\|ryP	NUj0e2RwW0GQR1XS
IA-LM	M3PRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTtTWM2OD1{Nj6zOlQ2KM7:TR?=	MYXTRW5ITVJ?
GP5d	M1G2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfQcJpKSzVyPUK2MlQ1QTFizszN	NXPqVWtJW0GQR1XS
NCI-H2291	NIDhPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTlR4RKSzVyPUK2MlY2PDFizszN	NWTFcYRrW0GQR1XS
BALL-1	M1XHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJ4LkmzPVch\|ryP	NV;IOXR2W0GQR1XS
HCC1954	Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXLTWM2OD1{Nj65PFA5KM7:TR?=	NYXIbnd3W0GQR1XS
NCI-H2452	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDme2xKSzVyPUK3MlQyPjNizszN	M2PYSHNCVkeHUh?=
LU-99A	M3j2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2K1TGlEPTB;MkeuOVU5OiEQvF2=	M1XwVnNCVkeHUh?=
NTERA-S-cl-D1	M3roU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJ5LkeyPVkh\|ryP	M2HxXXNCVkeHUh?=
PANC-10-05	M3vEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTJ5Lke3O\|Uh\|ryP	MnHRV2FPT0WU
NCI-H2405	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnvWI5KSzVyPUK3Mlk{QDdizszN	MofXV2FPT0WU
MDA-MB-415	NV75OmhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPDTWM2OD1{OD60NVM4KM7:TR?=	M2DJOnNCVkeHUh?=
NCI-H2342	M3q4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnW[HliUUN3ME2yPE42OjhzIN88US=>	MXLTRW5ITVJ?
TGBC24TKB	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJ6LkexNVch\|ryP	MlTMV2FPT0WU
LU-134-A	NHGwc\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzkTWM2OD1{OD65NlYyKM7:TR?=	MYrTRW5ITVJ?
SCC-4	NH:4b49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4n0TGlEPTB;M{GuNFQ6PCEQvF2=	NV35XpFOW0GQR1XS
Saos-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTNzLkmzNFYh\|ryP	MYPTRW5ITVJ?
RERF-LC-MS	M{Dud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTN{LkiyN\|Eh\|ryP	MXvTRW5ITVJ?
M14	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVS4O4NtUUN3ME2zNk46PzZ2IN88US=>	NV7sW\|JuW0GQR1XS
HPAF-II	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTN\|LkWwNVEh\|ryP	NX;rcHhMW0GQR1XS
NCI-H1755	NWPyZ\|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;HW3hGUUN3ME2zOE4{OzB3IN88US=>	NHS0RolUSU6JRWK=
D-392MG	NW\SZlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfoNFRKSzVyPUO1Mlg3PzRizszN	MUjTRW5ITVJ?
A704	MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTN4LkC0Nlch\|ryP	NVjTdVNpW0GQR1XS
CP50-MEL-B	M2Pu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHy3TXVKSzVyPUO2MlE6OTFizszN	M33FXnNCVkeHUh?=
EW-18	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGL6VGhKSzVyPUO2MlQ2OiEQvF2=	Ml7DV2FPT0WU
WM-115	NXP0[JVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrWU3lKSzVyPUO2MlgxQTlizszN	NXTKVJlHW0GQR1XS
LU-65	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\LcWlEPTB;M{euNVQyPyEQvF2=	NFjiTW9USU6JRWK=
NCI-H1563	NU\ucoR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvyVYlxUUN3ME2zO{4zPDh2IN88US=>	M3jqVnNCVkeHUh?=
DBTRG-05MG	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TmTGlEPTB;M{iuNFY6OSEQvF2=	MUfTRW5ITVJ?
NCI-H630	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTN6LkS3NVQh\|ryP	M4nDeHNCVkeHUh?=
NCI-H1155	M4DXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFv5RlBKSzVyPUO5MlI1OiEQvF2=	MV7TRW5ITVJ?
OVACR-3	NX7Hc\|BGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGroT2pKSzVyPUO5MlkyQTVizszN	NUTPXo5lW0GQR1XS
OAW-42	M{LDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPxTWM2OD12MD60NlU5KM7:TR?=	NVvVW291W0GQR1XS
JVM-2	M2WxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3lTGJUUUN3ME20NU4zPDF3IN88US=>	Mnu3V2FPT0WU
C3A	M3PubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTRzLkO0OFch\|ryP	MUfTRW5ITVJ?
HT55	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTR{LkK4OFEh\|ryP	NHLjWZRUSU6JRWK=
OVCAR-4	M3HVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\YfGVKSzVyPUSyMlI6PzRizszN	NVTjbZMzW0GQR1XS
MEG-01	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzlWoxKSzVyPUSyMlQ3OTZizszN	NFywZ\|VUSU6JRWK=
NCI-H82	NEfPRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mon1TWM2OD12Mz65PFkzKM7:TR?=	M3m3T3NCVkeHUh?=
JEG-3	NYj2O4dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz1dmpKSzVyPUS0Mlk1PyEQvF2=	M{P5UHNCVkeHUh?=
BPH-1	NED1W2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn1TWM2OD12Nj6zPVk5KM7:TR?=	MVjTRW5ITVJ?
MPP-89	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTR5LkK4PVgh\|ryP	Ml7CV2FPT0WU
ALL-PO	M1jRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTR5LkSxPFgh\|ryP	MVjTRW5ITVJ?
HT	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zYd2lEPTB;NEeuOFkzKM7:TR?=	Mmf6V2FPT0WU
NCI-H2347	NFLiPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof3TWM2OD12OD6wO\|E2KM7:TR?=	MVPTRW5ITVJ?
A2780	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTZUWtkUUN3ME20PU41OjJ6IN88US=>	NV;yTYxNW0GQR1XS
KARPAS-299	NVvvVY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTIU2IxUUN3ME20PU42OTF7IN88US=>	M4\zOHNCVkeHUh?=
NCI-H1651	NH;ke2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlviTWM2OD12OT64PFIyKM7:TR?=	NFHqR2tUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04483505	Not yet recruiting	Drug: Combination Rogaratinib + palbociclib + fulvestrant	Breast Cancer Metastatic\|Hormone Receptor Positive Malignant Neoplasm of Breast	Fundacion CRIS de Investigación para Vencer el Cáncer\|Bayer\|Pfizer\|Apices Soluciones S.L.	October 1 2020	Phase 1
NCT04360941	Recruiting	Drug: Palbociclib\|Drug: Avelumab	Triple Negative Breast Cancer\|Locally Advanced Breast Cancer\|Recurrent Breast Cancer\|Metastatic Breast Cancer\|ER+ Breast Cancer\|HER2-positive Breast Cancer	Royal Marsden NHS Foundation Trust\|Pfizer\|Breast Cancer Now	August 11 2020	Phase 1
NCT03870919	Suspended	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 23 2019	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (Seliciclib)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl